Small trial targeting Epstein-Barr infections shows promise as multiple sclerosis treatment
Coronaviruses evolve to recognize glycans of their host species
13 April 2022Different stroke symptoms could be making them harder to spot early in women
13 April 2022Small trial targeting Epstein-Barr infections shows promise as multiple sclerosis treatment
A team of researchers at Atara Biotherapeutics has conducted a small Phase I clinical trial of a therapeutic called ATA188 that targets Epstein-Barr infections (EBV) as a treatment for multiple sclerosis (MS). Representatives from Atara Biotherapeutics presented their findings at an EBV and MS Day event. A press release from late last year described the results of their clinical trial.
